Maria Rosario1, Timothy Wyant2,3, Timothy Leach2, Serap Sankoh2, Catherine Scholz2,4, Asit Parikh2, Irving Fox2, Brian G Feagan5. 1. Millennium Pharmaceuticals, Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company, Ltd.), Cambridge, MA, USA. maria.rosario@takeda.com. 2. Millennium Pharmaceuticals, Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company, Ltd.), Cambridge, MA, USA. 3. Curis, Inc., Lexington, MA, USA. 4. Kura Oncology, Inc., Cambridge, MA, USA. 5. Robarts Research Institute, University of Western Ontario, London, ON, Canada.
Abstract
BACKGROUND AND OBJECTIVES:Vedolizumab, a humanized monoclonal antibody against the α4β7 integrin, is indicated for treatment of moderately to severely active ulcerative colitis or Crohn's disease. In this placebo-controlled, double-blind, randomized, single ascending-dose study, the pharmacokinetics, pharmacodynamics, safety, and tolerability of vedolizumab were evaluated in healthy volunteers. METHODS:Forty-nine participants (in five cohorts) were randomly assigned in a 4:1 ratio to receive a single intravenous infusion of either vedolizumab (0.2, 0.5, 2.0, 6.0, or 10.0 mg/kg) or placebo. Blood samples were collected for measurement of vedolizumab serum concentrations and α4β7 saturation on peripheral blood lymphocytes by vedolizumab. Pharmacokinetic parameters were computed using a non-compartmental approach. Adverse events were monitored. RESULTS:Vedolizumab maximum observed serum concentration (C max) demonstrated dose proportionality over the dose range tested. Greater than dose-proportional increases in area under the serum concentration-time curve from time 0 to infinity (AUC0-inf) and shorter terminal elimination half-life (t 1/2) were observed from 0.2 to 2.0 mg/kg, suggestive of nonlinear pharmacokinetics at lower doses. At doses higher than 2.0 mg/kg, these parameters increased dose proportionally. Saturation of α4β7 was at or near maximal levels (>90 %) at all doses and time points when vedolizumab was measurable in serum. A total of 21 of 39 (54 %) vedolizumab-treated participants were anti-drug antibody (ADA) positive, and 11 (28 %) were persistently ADA positive. Overall, no adverse event signals, including serious infections or malignancies, were apparent. CONCLUSIONS:Vedolizumab exhibited target-mediated disposition, characterized by a rapid, saturable, nonlinear elimination process at low concentrations and a slower linear elimination process at higher concentrations. Nearly complete α4β7 saturation was observed at all doses. A single intravenous infusion of vedolizumab was well tolerated by healthy volunteers.
RCT Entities:
BACKGROUND AND OBJECTIVES:Vedolizumab, a humanized monoclonal antibody against the α4β7 integrin, is indicated for treatment of moderately to severely active ulcerative colitis or Crohn's disease. In this placebo-controlled, double-blind, randomized, single ascending-dose study, the pharmacokinetics, pharmacodynamics, safety, and tolerability of vedolizumab were evaluated in healthy volunteers. METHODS: Forty-nine participants (in five cohorts) were randomly assigned in a 4:1 ratio to receive a single intravenous infusion of either vedolizumab (0.2, 0.5, 2.0, 6.0, or 10.0 mg/kg) or placebo. Blood samples were collected for measurement of vedolizumab serum concentrations and α4β7 saturation on peripheral blood lymphocytes by vedolizumab. Pharmacokinetic parameters were computed using a non-compartmental approach. Adverse events were monitored. RESULTS:Vedolizumab maximum observed serum concentration (C max) demonstrated dose proportionality over the dose range tested. Greater than dose-proportional increases in area under the serum concentration-time curve from time 0 to infinity (AUC0-inf) and shorter terminal elimination half-life (t 1/2) were observed from 0.2 to 2.0 mg/kg, suggestive of nonlinear pharmacokinetics at lower doses. At doses higher than 2.0 mg/kg, these parameters increased dose proportionally. Saturation of α4β7 was at or near maximal levels (>90 %) at all doses and time points when vedolizumab was measurable in serum. A total of 21 of 39 (54 %) vedolizumab-treated participants were anti-drug antibody (ADA) positive, and 11 (28 %) were persistently ADA positive. Overall, no adverse event signals, including serious infections or malignancies, were apparent. CONCLUSIONS:Vedolizumab exhibited target-mediated disposition, characterized by a rapid, saturable, nonlinear elimination process at low concentrations and a slower linear elimination process at higher concentrations. Nearly complete α4β7 saturation was observed at all doses. A single intravenous infusion of vedolizumab was well tolerated by healthy volunteers.
Authors: Asit Parikh; Timothy Leach; Tim Wyant; Catherine Scholz; Serap Sankoh; Diane R Mould; Terry Ponich; Irving Fox; Brian G Feagan Journal: Inflamm Bowel Dis Date: 2011-12-06 Impact factor: 5.325
Authors: Brian G Feagan; Gordon R Greenberg; Gary Wild; Richard N Fedorak; Pierre Paré; John W D McDonald; Rejean Dubé; Albert Cohen; A Hillary Steinhart; Steven Landau; Rasha A Aguzzi; Irving H Fox; Margaret K Vandervoort Journal: N Engl J Med Date: 2005-06-16 Impact factor: 91.245
Authors: Bruce E Sands; Brian G Feagan; Paul Rutgeerts; Jean-Frédéric Colombel; William J Sandborn; Richmond Sy; Geert D'Haens; Shomron Ben-Horin; Jing Xu; Maria Rosario; Irving Fox; Asit Parikh; Catherine Milch; Stephen Hanauer Journal: Gastroenterology Date: 2014-05-21 Impact factor: 22.682
Authors: Brian G Feagan; Gordon R Greenberg; Gary Wild; Richard N Fedorak; Pierre Paré; John W D McDonald; Albert Cohen; Alain Bitton; Jeffrey Baker; Réjean Dubé; Steven B Landau; Margaret K Vandervoort; Asit Parikh Journal: Clin Gastroenterol Hepatol Date: 2008-10-01 Impact factor: 11.382
Authors: Brian G Feagan; Paul Rutgeerts; Bruce E Sands; Stephen Hanauer; Jean-Frédéric Colombel; William J Sandborn; Gert Van Assche; Jeffrey Axler; Hyo-Jong Kim; Silvio Danese; Irving Fox; Catherine Milch; Serap Sankoh; Tim Wyant; Jing Xu; Asit Parikh Journal: N Engl J Med Date: 2013-08-22 Impact factor: 91.245
Authors: M Rosario; N L Dirks; M R Gastonguay; A A Fasanmade; T Wyant; A Parikh; W J Sandborn; B G Feagan; W Reinisch; I Fox Journal: Aliment Pharmacol Ther Date: 2015-05-20 Impact factor: 8.171
Authors: Jean-Frédéric Colombel; Bruce E Sands; Paul Rutgeerts; William Sandborn; Silvio Danese; Geert D'Haens; Remo Panaccione; Edward V Loftus; Serap Sankoh; Irving Fox; Asit Parikh; Catherine Milch; Brihad Abhyankar; Brian G Feagan Journal: Gut Date: 2016-02-18 Impact factor: 23.059
Authors: Eugenia Shmidt; Gursimran Kochhar; Justin Hartke; Prianka Chilukuri; Joseph Meserve; Khadija Chaudrey; Jenna L Koliani-Pace; Robert Hirten; David Faleck; Morris Barocas; Michelle Luo; Karen Lasch; Brigid S Boland; Siddharth Singh; Niels Vande Casteele; Sashidhar Varma Sagi; Monika Fischer; Shannon Chang; Matthew Bohm; Dana Lukin; Keith Sultan; Arun Swaminath; David Hudesman; Nitin Gupta; Sunanda Kane; Edward V Loftus; William J Sandborn; Corey A Siegel; Bruce E Sands; Jean-Frederic Colombel; Bo Shen; Parambir S Dulai Journal: Inflamm Bowel Dis Date: 2018-10-12 Impact factor: 5.325
Authors: Robert Battat; Parambir S Dulai; Niels Vande Casteele; Elisabeth Evans; Kelly D Hester; Edvelyn Webster; Anjali Jain; James A Proudfoot; Ara Mairalles; Jennifer Neill; Siddharth Singh; John T Chang; Jesus Rivera-Nieves; William J Sandborn; Brigid S Boland Journal: Inflamm Bowel Dis Date: 2019-01-10 Impact factor: 5.325
Authors: Christina Guzzo; David Ichikawa; Chung Park; Damilola Phillips; Qingbo Liu; Peng Zhang; Alice Kwon; Huiyi Miao; Jacky Lu; Catherine Rehm; James Arthos; Claudia Cicala; Myron S Cohen; Anthony S Fauci; John H Kehrl; Paolo Lusso Journal: Sci Immunol Date: 2017-05-12
Authors: Jacob E Ollech; Inessa Normatov; Noam Peleg; Jingzhou Wang; Shivani A Patel; Victoria Rai; Yangtian Yi; Jorie Singer; Sushila R Dalal; Atsushi Sakuraba; Russell D Cohen; David T Rubin; Joel Pekow Journal: Clin Gastroenterol Hepatol Date: 2020-02-26 Impact factor: 11.382